ReviewJournal of gastrointestinal cancer2017
Liver Transplantation for Hepatocellular Carcinoma at Inonu University.
Review in Journal of gastrointestinal cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Modeling the Health Economic Burden of Hepatitis C Virus Infection in Turkey: Cost-Effectiveness of Targeted Screening.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2023Review
- Parameters Predicting Microvascular Invasion and Poor Differentiation in Hepatocellular Carcinoma Patients with Normal Alpha-fetoprotein Level Before Liver Transplantation.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2023Article
- Liver transplantation for hepatocellular carcinoma: Historical evolution of transplantation criteria.World journal of clinical cases · 2022Review
- Are the criteria always right? Assessment of hepatocellular carcinoma cases in living donor liver transplantation at a high-volume centerTurkish journal of medical sciences · 2021Article
- Malatya and Other Criteria for Liver Transplantation in Hepatocellular Carcinoma.Journal of gastrointestinal cancer · 2020Review
- HCC and Tumor Biomarkers: Does One Size Fits All?Journal of gastrointestinal cancer · 2020Review
- Living Donor Versus Deceased Donor Liver Transplantation for HCC.Journal of gastrointestinal cancer · 2020Review
- Liver Transplantation for Hepatocellular Carcinoma: Malatya Experience and Proposals for Expanded Criteria.Journal of gastrointestinal cancer · 2020Article
- Deceased donor liver transplantation from donors with central nervous system malignancy: Experience of the Inonu University.Northern clinics of Istanbul · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is a great effort in the world to find a new drug in hepatocellular carcinoma (HCC) treatment. Turkey has a limited number of basic science studies to discover a new therapeutic drug for HCC. It seems that Turkey is distanced from the global drug discovery race and competition, however, Turkey has the advantage of a wide experience in living donor liver transplantation, like South Korea and Japan. Turkey can plan new studies on HCC, particularly with living donor liver transplantation. Neoadjuvant treatment methods before living donor liver transplantation for advanced tumors would be a good idea for study in Turkey. Because Inonu University has the busiest liver transplantation program in Turkey, the contribution of Inonu University to trials like this can improve the depth of the studies. To conclude, the Inonu University Liver Transplantation Institute has the busiest program in Turkey with 1,600 transplantations in eight years. The program is based on living donor liver transplantations (80%). Living donor liver transplantation for advanced HCC patients is our favorite topic to study.
Indexed as
Identifiers
28674912What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.